Search and Filter
Results per Page:
Novel regimen greatly reduced chronic GVHD in phase 2 study at Fred Hutch
Substituting cyclophosphamide for a standard post-transplant immunosuppressant is a “gamechanger”
Dr. Sara Hurvitz receives the Smith Family Endowed Chair in Women’s Health
Flexible funding will fuel physician-scientist’s work to improve survivorship for women with cancer
Surprising findings about blood cell mutations bode well for transplant recipients
Fred Hutch researchers compared blood samples from 16 recipient-donor pairs, some more than 45 years after transplant
50 years of doing hard things
Founded in 1975 to honor a brother, Fred Hutch Cancer Center pursued bold science, pioneered a cure for blood diseases that changed medicine and became a world-class biomedical research and clinical care institution
Starting the year smarter
How patients, providers, researchers and others stay informed amid a deluge of data and information
Fred Hutch Phase 1 Program director, Dr. John Thompson, retires
An immunotherapy champion, Thompson co-led the melanoma clinic for decades
A charming model: new tool evaluates risk of transplant for older patients
Seven values are evaluated to predict outcomes
New funding drives six breast cancer studies
Scientists from Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium receive $1.7M in grants from Breast Cancer Research Foundation
Dr. Mazyar Shadman, new medical director of the Bezos Family Immunotherapy Clinic, says immunotherapy services are expanding to meet demand
Increasing timely access to immunotherapy is a main goal
New biomarker could one day help tailor immunotherapy for Merkel cell carcinoma
Helps explain why only certain MCC patients respond to immune checkpoint inhibitors, could point toward new strategies to improve treatment responses
Reducing frequency of immunotherapy dosing could save money and time, keep patients on therapy longer
Study of immune checkpoint inhibitor dosing in patients with advanced skin cancers could help guide long-term treatment plans
Multiple myeloma research to be presented at American Society of Hematology annual meeting
Dr. Rahul Banerjee to share insights on reducing financial toxicity, time toxicity and side effects of treatment
Big-picture approach helps identify experimental diagnostic to personalize ovarian cancer treatment
Team uses large-scale proteogenomic changes to identify which patients should look beyond standard treatment options
Bioengineer Aaron Ring receives Anderson Family Endowed Chair for Immunotherapy
Chair will support innovative immunotherapeutic approaches to cancer drug target discovery
Project Stella enables novel pediatric AML immunotherapies, potential cure
Fred Hutch's Dr. Soheil Meshinchi's lab identifies potential drug while also developing immunotherapy thanks to fundraising
Peripheral neuropathy: When having no pain is a big problem
Chemotherapy-induced nerve damage is common for cancer patients and difficult to treat
Immunotherapy helps retired fisheries biologist get back to normal
Advanced chondrosarcoma – 'shark' cancer – has no standard treatments beyond surgery, but Fred Hutch oncologist explores new option for patient
Dr. Fred Appelbaum receives Lifetime Achievement award
Medical pioneer and longtime Fred Hutch leader honored by American Society for Transplantation and Cellular Therapy
Leader in apheresis and cellular therapy, Dr. Michael Linenberger, retires
As professor emeritus, this respected mentor will continue to contribute to the UW fellowship program
Eight Fred Hutch teams win Evergreen Fund awards
Research projects with commercial partnership potential receive grants of up to $200K